The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

15 articles for P Ettmayer


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors.EBI
Sandoz Forschungsinstitut Ges.M.B.H.
 
Novel, extended transition state mimic in HIV-1 protease inhibitors with peripheral C-2-symmetryEBI
TBA
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.EBI
Boehringer Ingelheim Rcv
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.EBI
Boehringer Ingelheim Rcv
S(+)-4-(1-Phenylethylamino)quinazolines as inhibitors of human immunoglobulin E synthesis: potency is dictated by stereochemistry and atomic point charges at N-1.EBI
Novartis Forschungsinstitut
Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).EBI
Novartis Forschungsinstitut
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor EBI
Boehringer Ingelheim Rcv
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.EBI
Boehringer Ingelheim Rcv
NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.EBI
Novartis Institutes For Biomedical Research
Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex.BDB
Stony Brook University
Tyrosine kinase inhibitorsBDB
Principia Biopharma
Methods for treating seizure disorders and painBDB
University of California
1,2,5-Substituted benzimidazoles as flap modulatorsBDB
Janssen Pharmaceutica